nitrendipine has been researched along with Breast Cancer, Male in 1 studies
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jacobs, U | 1 |
| Klein, B | 1 |
| Klehr, HU | 1 |
1 other study available for nitrendipine and Breast Cancer, Male
| Article | Year |
|---|---|
Cumulative side effects of cyclosporine and Ca antagonists: hypergalactinemia, mastadenoma, and gynecomastia.
Topics: Adenoma; Adult; Aged; Breast Neoplasms, Male; Calcium Channel Blockers; Cyclosporine; Diltiazem; Dru | 1994 |